 |
|
Study identifies potential drug target for Huntington's disease
July 31, 2006Blocking enzyme action could protect against energy depletion in several disorders
An enzyme known to be critical for the repair of damaged cells and the maintenance of cellular energy may be a useful target for new strategies to treat Huntington's disease (HD) and other disorders characterized by low cellular energy levels. In the August issue of Chemistry & Biology, a research team from the MassGeneral Institute for Neurodegenerative Disease (MIND) describes their discovery of a novel inhibitor of Poly (ADP-ribose) polymerase (PARP1) and their findings that PARP1 inhibitors can protect HD-affected cells from damage in laboratory assays.
"While PARP1 is essential for the repair of damaged DNA, we also know that, if overactivated, it can cause cell death by excessive energy depletion," says Aleksey Kazantsev, PhD, director of the MIND High Throughput Drug Screening Laboratory, who led the current study. "It has recently been shown that neurons from patients with Huntington's appear to be energy-deficient, so we hypothesized that modest stresses that would be tolerated by healthy cells could send HD cells below a viable energy threshold and that blocking PARP1 activation could be protective."
To test this hypothesis the MIND researchers first ran a computer search of their small-molecule library for potential novel inhibitors of PARP1, searching for those with structural similarities to known inhibitors. "Safety and efficacy of human drugs depends on many factors, so it's hard to predict which inhibitor would be most effective against a specific disorder. The more diverse novel inhibitors can be identified, the more chances there are of developing safe and effective drugs," Kazantsev explains.
Two candidate molecules were identified as potential PARP1 inhibitors based on their structure, and both of them were confirmed to inhibit the enzyme's activity in an in vitro assay. However, when tested using cultured human and rat cells, only one of the candidate molecules, K245-14, successfully prevented the death of cells in which PARP1 had been overactivated.
The next assays examined whether blocking PARP1 activity with K245-14 could reduce energy depletion in cells with the HD genetic mutation. Using cells from human HD patients and from a mouse model of the disorder, the MIND researchers compared the reactions of HD cells to oxidative stress caused by the application of hydrogen peroxide with the reactions of normal cells. Although all of the cells reacted with a loss of ATP, a key source of cellular energy, the HD cells - which had much lower ATP levels to begin with - were much more vulnerable to stress-induced energy loss. Inhibiting PARP1 by means of K245-14 reduced ATP loss in all tested cells and significantly protected against both energy loss and cell death in the HD cells.
"While we were pleased to observe these predicted protective effects in our experiments, validation of PARP1 as a useful HD drug target will require the testing of inhibitors in animal trials," Kazantsev explains. "The process of identifying the best candidates for trials will be very complex, since any drug treating a central nervous system disorder needs to penetrate the blood-brain barrier. We will be working with our collaborators at the Scripps Research Institute - world leaders in computational chemistry - to conduct a more comprehensive virtual screen and select additional promising candidates for drug development.
"Inhibition of PARP1 activity is thought to be potentially beneficial for treatment of cancer, neurodegenerative conditions such as Parkinson's disease, and over twenty other human disorders," he adds. "We envision broad therapeutic applications for small molecule inhibitors of PARP1.\\\
Massachusetts General Hospital
To test this hypothesis the MIND researchers first ran a computer search of their small-molecule library for potential novel inhibitors of PARP1, searching for those with structural similarities to known inhibitors. "Safety and efficacy of human drugs depends on many factors, so it's hard to predict which inhibitor would be most effective against a specific disorder. The more diverse novel inhibitors can be identified, the more chances there are of developing safe and effective drugs," Kazantsev explains.
Two candidate molecules were identified as potential PARP1 inhibitors based on their structure, and both of them were confirmed to inhibit the enzyme's activity in an in vitro assay. However, when tested using cultured human and rat cells, only one of the candidate molecules, K245-14, successfully prevented the death of cells in which PARP1 had been overactivated.
The next assays examined whether blocking PARP1 activity with K245-14 could reduce energy depletion in cells with the HD genetic mutation. Using cells from human HD patients and from a mouse model of the disorder, the MIND researchers compared the reactions of HD cells to oxidative stress caused by the application of hydrogen peroxide with the reactions of normal cells. Although all of the cells reacted with a loss of ATP, a key source of cellular energy, the HD cells - which had much lower ATP levels to begin with - were much more vulnerable to stress-induced energy loss. Inhibiting PARP1 by means of K245-14 reduced ATP loss in all tested cells and significantly protected against both energy loss and cell death in the HD cells.
"While we were pleased to observe these predicted protective effects in our experiments, validation of PARP1 as a useful HD drug target will require the testing of inhibitors in animal trials," Kazantsev explains. "The process of identifying the best candidates for trials will be very complex, since any drug treating a central nervous system disorder needs to penetrate the blood-brain barrier. We will be working with our collaborators at the Scripps Research Institute - world leaders in computational chemistry - to conduct a more comprehensive virtual screen and select additional promising candidates for drug development.
"Inhibition of PARP1 activity is thought to be potentially beneficial for treatment of cancer, neurodegenerative conditions such as Parkinson's disease, and over twenty other human disorders," he adds. "We envision broad therapeutic applications for small molecule inhibitors of PARP1.\\\
Massachusetts General Hospital
Huntingtons Disease Current Events and Huntingtons Disease News RSSMayo discovers link between Huntington's and abnormal cholesterol levels in brain
Mayo Clinic researchers have discovered a protein interaction that may explain how the deadly Huntington's disease affects the brain.
Test reveals effectiveness of potential Huntington's disease drugs
A test using cultured cells provides an effective way to screen drugs against Huntington's disease and shows that two compounds-memantine and riluzole - are most effective at keeping cells alive under conditions that mimic the disorder, UT Southwestern Medical Center researchers report.
Test reveals effectiveness of potential Huntington's disease drugs
A test using cultured cells provides an effective way to screen drugs against Huntington's disease and shows that two compounds - memantine and riluzole - are most effective at keeping cells alive under conditions that mimic the disorder, UT Southwestern Medical Center researchers report.
New technology to speed up research into Huntington's disease
A new tool developed at Cambridge University represents a breakthrough in the race to find treatments to help sufferers with Huntington's disease.
"Booster rocket" malfunction implicated in Huntington's disease
CNRS and Inserm research scientists at the Institut Curie have shed new light on the function of huntingtin, the protein whose mutation underlies Huntington's disease. This neurodegenerative disease, like Alzheimer's or Parkinson's, is characterized by the abnormal death of certain neurons. The scientists have discovered that huntingtin, like a "booster rocket", accelerates the transport of a neuron survival factor. When huntingtin is mutated, the "booster rocket" malfunctions, transport slows, protection wanes, and neurons die. This discovery, published in the 9 July 2004 issue of Cell, could in time lead to novel therapeutic methods of blocking the accelerated death of neurons.
Could A Protein Have Saved Salem's Witches From Burning At The Stake?
Huntington's disease (HD), a fatal degenerative disorder of the brain, can be alleviated by administration of a protein known to promote neuron survival, say scientists in the January's journal Experimental Neurology.
A new pathway for halting neuronal death in Huntington's disease
The body is an extremely complex puzzle in which every piece plays a critical role. Should pieces disappear harmony is compromised. Such is the case with certain neurodegenerative diseases; when neurons suddenly die, the body's ability to function properly is jeopardized. CNRS (1) and INSERM biologists from the Curie Institute are working to understand how neurons die in one specific neurodegenerative disease: Huntington's disease. They have just announced the discovery of two new factors capable of blocking cell death induced in Huntington's disease. They may eventually provide targets for the therapeutic treatment of this type of disease. These discoveries were published in the 7th of Ju
Patients' views about their illness can help treatment planning
What is it like to be chronically ill? Those people with severe illnesses such as Huntington's disease or multiple sclerosis do not see their illness in the same way as health professionals do. Associate professor Ad Kaptein, Leiden University, Netherlands organised an international symposium on patients' representations of their illnesses at the joint British Psychological Society's Division of Health Psychology and European Health Psychology Society conference held at St Andrews University, today, Wednesday 5 September. Health psychologists from Portugal, New Zealand, the Netherlands and the UK were discussing the following research. Multiple Sclerosis is a chronic, incurable and debili
More Huntingtons Disease Current Events and Huntingtons Disease News Articles
 | The Woman Who Walked into the Sea: Huntington's and the Making of a Genetic Disease by Alice Wexler A groundbreaking medical and social history of a devastating hereditary neurological disorder once demonized as “the witchcraft disease” When Phebe Hedges, a woman in East Hampton, New York, walked into the sea in 1806, she made visible the historical experience of a family affected by the dreaded disorder of movement, mind, and mood her neighbors called St.Vitus's dance. Doctors later... |
 | A New Promise by Julie Eller |
 | Stem Cell Symphony: A Novel by Ricki Lewis Stuart Matheson, 32, is trapped in a nursing home as well as his body, eerily immobile at the last stage of Huntington's Disease. Kelsey Raye is a science writer feeling guilty about the recent deaths of her parents. She volunteers for hospice and is assigned to Stuart. She's a PhD, he never finished school, but they share a love of rock music... |
 | Portraits of Huntington's by Carmen Leal Portraits of Huntington's is a joyful collection of profiles, essays, and quotes for and about those with Huntington's Disease. Portraits of Huntington'sfeatures award winning artist Ruth Hargrave's incredible portraits of eight individuals or family groups who are all in some way touched by this genetic disease. Joy is a choice. Happiness is based on a set of circumstances, and Portraits of... |
 | Blue Institution by Ernie Kish Scott Porter, institutionalized at the age of twenty in a state institution for the developmentally delayed. Ironically, Scott is not developmentally delayed. He suffers from a hereditary neurological disease, Huntington's chorea, which Scott admits is "one of Mother Nature's cruelest jokes."Huntington's has rendered Scott virtually unable to do anything for himself, including communicating... |
 | Huntington's Disease (The Facts) by Oliver W J Quarrell Huntington's disease is a genetically inherited condition which results in severe nerve-cell damage in the brain. The hereditary and debilitative nature of the disease means that many people are involved either directly or indirectly by this condition. The recent identification of the faulty gene involved has made the diagnosis of this condition simpler. The majority of people develop the disease... |
 | The Test: Living in the Shadow of Huntington's Disease by Jean Barema |
 | Learning to Live With Huntington's Disease: One Family's Story by Sandy Sulaiman |
 | Huntington's Disease (Genetic Diseases) by Johanna Knowles |
| Huntington disease: An entry from Thomson Gale's Gale Encyclopedia of Neurological Disorders by Deepti, MS, CGC Babu Targeted to patients, their families and allied health students, The “Gale Encyclopedia of Neurological Disorders” provides in-depth coverage of neurological diseases and disorders, including stroke, multiple sclerosis, Parkinson disease, Tourette Syndrome, Alzheimer's disease, cerebral palsy, vertigo, amnesia and epilepsy. Related topics include communication aids, electric personal... |
| © 2008 BrightSurf.com |